ID

23356

Beschrijving

A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients; ODM derived from: https://clinicaltrials.gov/show/NCT00360334

Link

https://clinicaltrials.gov/show/NCT00360334

Trefwoorden

Versies (1)
  1. 03-07-17 03-07-17 -
Geüploaded op

3 juli 2017

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Type 2 Diabetes NCT00360334

Engels

Eligibility Type 2 Diabetes NCT00360334

1 Formulieren  
Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosed with type 2 diabetes
Beschrijving

Diabetes Mellitus, Non-Insulin-Dependent

Datatype

boolean

Alias
UMLS CUI [1]
C0011860
currently being treated with the following: dual or triple oral therapy - on a stable combination and dose for at least 3 months.
Beschrijving

Therapeutic procedure Oral Duplicate | Therapeutic procedure Oral Triplicate | Combined Modality Therapy Dose Stable

Datatype

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C1527415
UMLS CUI [1,3]
C0205173
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C1527415
UMLS CUI [2,3]
C0205174
UMLS CUI [3,1]
C0009429
UMLS CUI [3,2]
C0178602
UMLS CUI [3,3]
C0205360
hba1c between 7.5% and 10.0%.
Beschrijving

Glycosylated hemoglobin A

Datatype

boolean

Alias
UMLS CUI [1]
C0019018
bmi >27.
Beschrijving

Body mass index

Datatype

boolean

Alias
UMLS CUI [1]
C1305855
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
receive chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within 2 weeks immediately prior to study.
Beschrijving

Glucocorticoid therapy systemic chronic | Topical glucocorticoid | Glucocorticoids Inhalation

Datatype

boolean

Alias
UMLS CUI [1,1]
C0744425
UMLS CUI [1,2]
C0205373
UMLS CUI [1,3]
C0205191
UMLS CUI [2]
C0017712
UMLS CUI [3,1]
C0017710
UMLS CUI [3,2]
C0205535
have participated in an interventional medical, surgical, or pharmaceutical study (a study in which a medical or surgical treatment was given) within 30 days prior to entry into the study.
Beschrijving

Study Subject Participation Status | Interventional procedure | Therapeutic procedure | Operative Surgical Procedures | Investigational New Drugs

Datatype

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0184661
UMLS CUI [3]
C0087111
UMLS CUI [4]
C0543467
UMLS CUI [5]
C0013230
treatment with the following medications: *insulin as outpatient therapy within last 3 months; *meglitinides, or acarbose within the last 3 months; *regular use of any drugs that directly affect gastrointestinal motility; *any previous (study) therapy with exenatide or glucagon-like peptide-1 (glp-1) analogue; *anti-obesity agent use within the last 3 months.
Beschrijving

Insulin | Meglitinide | Acarbose | Pharmaceutical Preparations Affecting Gastrointestinal Motility | exenatide | Glucagon-Like Peptide 1 Analogue | Anti-Obesity Agents

Datatype

boolean

Alias
UMLS CUI [1]
C0021641
UMLS CUI [2]
C0065880
UMLS CUI [3]
C0050393
UMLS CUI [4,1]
C0013227
UMLS CUI [4,2]
C0392760
UMLS CUI [4,3]
C0017184
UMLS CUI [5]
C0167117
UMLS CUI [6,1]
C0061355
UMLS CUI [6,2]
C0243071
UMLS CUI [7]
C0376607
have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
Beschrijving

Drugs, Non-Prescription

Datatype

boolean

Alias
UMLS CUI [1]
C0013231
Terug naar het begin van de pagina

Similar models

Eligibility Type 2 Diabetes NCT00360334

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent
Item
diagnosed with type 2 diabetes
boolean
C0011860 (UMLS CUI [1])
Therapeutic procedure Oral Duplicate | Therapeutic procedure Oral Triplicate | Combined Modality Therapy Dose Stable
Item
currently being treated with the following: dual or triple oral therapy - on a stable combination and dose for at least 3 months.
boolean
C0087111 (UMLS CUI [1,1])
C1527415 (UMLS CUI [1,2])
C0205173 (UMLS CUI [1,3])
C0087111 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C0205174 (UMLS CUI [2,3])
C0009429 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C0205360 (UMLS CUI [3,3])
Glycosylated hemoglobin A
Item
hba1c between 7.5% and 10.0%.
boolean
C0019018 (UMLS CUI [1])
Body mass index
Item
bmi >27.
boolean
C1305855 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Glucocorticoid therapy systemic chronic | Topical glucocorticoid | Glucocorticoids Inhalation
Item
receive chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within 2 weeks immediately prior to study.
boolean
C0744425 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C0205191 (UMLS CUI [1,3])
C0017712 (UMLS CUI [2])
C0017710 (UMLS CUI [3,1])
C0205535 (UMLS CUI [3,2])
Study Subject Participation Status | Interventional procedure | Therapeutic procedure | Operative Surgical Procedures | Investigational New Drugs
Item
have participated in an interventional medical, surgical, or pharmaceutical study (a study in which a medical or surgical treatment was given) within 30 days prior to entry into the study.
boolean
C2348568 (UMLS CUI [1])
C0184661 (UMLS CUI [2])
C0087111 (UMLS CUI [3])
C0543467 (UMLS CUI [4])
C0013230 (UMLS CUI [5])
Insulin | Meglitinide | Acarbose | Pharmaceutical Preparations Affecting Gastrointestinal Motility | exenatide | Glucagon-Like Peptide 1 Analogue | Anti-Obesity Agents
Item
treatment with the following medications: *insulin as outpatient therapy within last 3 months; *meglitinides, or acarbose within the last 3 months; *regular use of any drugs that directly affect gastrointestinal motility; *any previous (study) therapy with exenatide or glucagon-like peptide-1 (glp-1) analogue; *anti-obesity agent use within the last 3 months.
boolean
C0021641 (UMLS CUI [1])
C0065880 (UMLS CUI [2])
C0050393 (UMLS CUI [3])
C0013227 (UMLS CUI [4,1])
C0392760 (UMLS CUI [4,2])
C0017184 (UMLS CUI [4,3])
C0167117 (UMLS CUI [5])
C0061355 (UMLS CUI [6,1])
C0243071 (UMLS CUI [6,2])
C0376607 (UMLS CUI [7])
Drugs, Non-Prescription
Item
have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
boolean
C0013231 (UMLS CUI [1])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial